Precise DX and COTA have partnered with Baptist Health South Florida to assess the performance of PreciseDx's AI-enabled PreciseBreast (PDxBr) test for assessing the risk of invasive breast cancer (IBC) recurrence.
The validation assessment will compare PDxBr’s results to traditional pathology reviews and 21-gene assay results. If the validation study is successful, Baptist Health has agreed to offer the test to its patients with IBC to expand access to the product within the oncology sector. The test is claimed to produce results in 48 hours at an 80% lower cost than conventional pathology solutions.
New York-based PreciseDx leverages advanced AI to analyze samples and provide patient-specific risk information. The company's key offerings include the PreciseDx platform, which helps patients and healthcare practitioners understand breast cancer diagnosis and determine personalized treatment plans.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.